Form D · Biotechnology
ARROGENE, INC
Los Angeles, CA · CIK 0001403792
Offering snapshot reported Oct 30, 2019 · SEC filing
- Reported sold
- $10K Offering amount: $990K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Oct 28, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 30, 2019 | Initial | $10,000 | No comparison | 1 | SEC filing |
| May 8, 2018 | Initial | $524,863 | No comparison | 14 | SEC filing |
| Mar 14, 2018 | Initial | $2,708,110 | No comparison | 43 | SEC filing |
| Mar 18, 2016 | Initial | $750,000 | No comparison | 1 | SEC filing |
| Jan 7, 2015 | Initial | $250,000 | No comparison | 1 | SEC filing |
| May 5, 2014 | Amendment | $700,000 | $200,000vs Apr 7, 2014 | 23 | SEC filing |
| Apr 7, 2014 | Amendment | $500,000 | $330,000vs Mar 7, 2014 | 17 | SEC filing |
| Mar 7, 2014 | Initial | $170,000 | No comparison | 6 | SEC filing |
| Mar 6, 2013 | Amendment | $2,272,250 | $130,000vs Jan 4, 2013 | 63 | SEC filing |
| Jan 4, 2013 | Amendment | $2,142,250 | -$1,632,250vs Jul 24, 2012 | 56 | SEC filing |
| Jan 4, 2013 | Amendment | $2,012,250 | -$1,762,250vs Jul 24, 2012 | 54 | SEC filing |
| Jul 24, 2012 | Amendment | $3,774,500 | $2,167,250vs Apr 5, 2012 | 51 | SEC filing |
| Apr 5, 2012 | Amendment | $1,607,250 | $495,250vs Feb 13, 2012 | 41 | SEC filing |
| Feb 13, 2012 | Amendment | $1,112,000 | $610,000vs Jan 23, 2012 | 10 | SEC filing |
| Jan 23, 2012 | Initial | $0 | No comparison | 11 | SEC filing |
| Jan 23, 2012 | Initial | $502,000 | No comparison | 16 | SEC filing |
| Jun 25, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-352164
If the offering is over-subscribed, the Company may, in its sole discretion accept subscriptions for an additional 200,000 shares at $0.90 per share for a total maximum offering amount of $1,170,000.
0
Source: Form D, filed Oct 30, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Larry A. Couture | Director, Executive |
| James Hosch | Director |
| Jack Kavanaugh | Director, Executive |
| Julia Ljubimova | Director, Executive |
| Robert Snukal | Director |
| Jeffrey Sperber | Executive |
| Robert Stuckelman | Director |
| Randolphe Swenson | Director |
| Maurizio Vecchione | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
12100 Wilshire Blvd. Ste. 800
Los Angeles, CA, 90025
Los Angeles, CA, 90025